Adjuvant Transarterial Chemoembolization After Truly Curative Resection Does Not Improve Survival of Patients With Hepatocellular Carcinoma at High Risk of Recurrence: A Target Trial Emulation Study

Documenti analoghi

• MR Radiomics Combined With Radiologic Features to Predict Recurrence Location in Nonviable Hepatocellular Carcinoma After Transarterial Chemoembolization
  di: Shuhang Zhang, et al.
  Pubblicazione: (2026)
• Clinical Impact of Recurrence Beyond the Milan Criteria After Curative Resection of Hepatocellular Carcinoma
  di: Takeshi Terashima, et al.
  Pubblicazione: (2025)
• Response to the Letter on “Role of ALBI Grade as a Predictive Factor for Long‐Term Mortality in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)”
  di: Kyoung A Ko, et al.
  Pubblicazione: (2026)
• Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy
  di: Nobuaki Ishihara, et al.
  Pubblicazione: (2025)
• Comments on “Immune Checkpoint Inhibitor‐Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: A Systematic Review and meta‐Analysis”
  di: Zheng Zhang, et al.
  Pubblicazione: (2026)